Cargando…

Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older

BACKGROUND: Older adults are given high priority for coronavirus disease 2019 (COVID-19) vaccination; however, little is known about the safety of vaccines. This study was conducted to examine the safety of the COVID-19 vaccine for people who were ≥ 75 years of age, specifically those who first took...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Youn Young, Kim, Min-Kyung, Kwon, Hyeok Choon, Kim, Gunn Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608922/ https://www.ncbi.nlm.nih.gov/pubmed/34811980 http://dx.doi.org/10.3346/jkms.2021.36.e318

Ejemplares similares

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose
por: Lim, Sung Hee, et al.
Publicado: (2023)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
por: Sa, Soonok, et al.
Publicado: (2022)

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine
por: Lim, Sung-Hee, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
por: Kim, Hyeonhui, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Reactive arthritis following COVID-19 vaccination with BNT162b2
por: Lebowitz, Emily, et al.
Publicado: (2022)

The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA Vaccine
por: Yoon, Bo Kyung, et al.
Publicado: (2022)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years
por: Romero-Olmedo, Addi J, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older
por: Kim, Jong Man, et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis
por: Lotan, Itay, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults
por: Um, Jihye, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
por: Walter, Emmanuel B., et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
por: Tan, Sharon H.X., et al.
Publicado: (2022)

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
por: Cohen-Stavi, Chandra J., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7bbp2aaof27ujbetjn0mf08nn9